10 principais bhvi.org concorrentes

myopiainstitute.org

Become a member Be part of a global collaboration of scientists, clinician and industry professionals wanting to make a difference for the individual patient, and the world, by preventing future sight threatening complications associated with myopia, based on the latest scientific research. Membership is free and includes: Access to the latest knowledge hot off the

endmyopia.org

Latest Shortsighted Podcast episode, now live. It’s maybe the most telling one of all of them yet. 20/15 is not that common and once you watch / listen to it, you’ll know why. You’ll also know how to…

myopiaprofile.com

an information resource to help eye care practitioners control progression of myopia in clinical practice, including education courses, downloads and blogs

shileyeye.ucsd.edu

the shiley eye institute is the only academic institution in the san diego area with comprehensive programs for the clinical care of patients with eye disorders, cutting edge research on surgical techniques and treatments of eye diseases, education in the field of ophthalmology and innovative outreach to the community.

clspectrum.com

Michael Moore, BSc(Hons) Optom, MSc, PhD, is a lecturer at the Technological University Dublin. He also conducts groundbreaking research in myopia. We talked about his recent paper on the risk of unco...

bmjophth.bmj.com

Objective To evaluate the literature-pooled functional, anatomical and safety outcomes of aflibercept biosimilars compared with reference aflibercept for neovascular age-related macular degeneration (nAMD).Methods and analysis Systematic review and meta-analysis. Medline, Embase and CENTRAL were searched from inception to 2 June 2025. Phase 3 randomised controlled trials (RCTs) comparing aflibercept biosimilars with the reference product in patients with nAMD were included. Two independent reviewers conducted screening, data extraction, risk of bias (RoB 2) assessment and certainty of evidence assessment (Grading of Recommendations, Assessment, Development and Evaluation), with a third reviewer resolving discrepancies. Primary outcomes included mean difference (MD) change in best-corrected visual acuity (BCVA) and retinal thickness over time, risk ratio (RR) for proportion of participants gaining >15 Early Treatment Diabetic Retinopathy Study (ETDRS) letters and RR for adverse events. Meta-regression was used to evaluate the temporal stability of continuous outcomes.Results Six RCTs involving 2044 participants (1026 biosimilar, 1018 reference) were included. Five aflibercept biosimilars were evaluated, representing more than 50% of the eight biosimilars currently approved worldwide. Meta-regression revealed no significant difference in MD change in BCVA over time between biosimilar and reference aflibercept (slope: 0.0321 letters/week; p=0.1013). For MD change in retinal thickness, an initial anatomical advantage for reference aflibercept at week 0 (intercept: 9.58 µm; p=0.0449) was not sustained over time (slope: –0.1685 µm/week; p=0.2303). The pooled RR for gaining >15 ETDRS letters from baseline was 1.19 (95% CI 0.98 to 1.45; p=0.079). No statistically significant differences were observed across 15 safety outcomes.Conclusion This systematic review and meta-analysis found no statistically significant differences in functional, anatomical or safety outcomes betwee

jnjvisionpro.com

Use the sitemap on this page to learn how to navigate our website and easily find the information you are looking for about our brand

coopervision.com

Global provider of contacts for your eyes: CooperVision provides a great choice for contact lens wearers worldwide. Our offical web site has product information and advice on contact lenses.

iapb.org

In our new report for World Sight Day, co-led by Seva Foundation, we make a first attempt to estimate the global loss of learning from uncorrected refractive error in schools.

escrs.org

ESCRS seeks to promote and support research in the field of intraocular lens implantation and refractive surgery and the dissemination of the useful results thereof. ESCRS has over 7,000 members from 130 countries world-wide.